Book contents
- Frontmatter
- Contents
- Contributors
- Foreword
- Preface
- Introduction
- PART I PHYSIOLOGY OF REPRODUCTION
- PART II INFERTILITY EVALUATION AND TREATMENT
- PART III ASSISTED REPRODUCTION
- 38 Medical Strategies to Improve ART Outcome: Current Evidence
- 39 Surgical Preparation of the Patient for In Vitro Fertilization
- 40 IVF in the Medically Complicated Patient
- 41 Polycystic Ovary Syndrome and IVF
- 42 Endometriosis and Assisted Reproductive Technology
- 43 Evidence-Based Medicine Comparing hMG/FSH and Agonist/Antagonist and rec/Urinary hCG/LH/GnRH to Trigger Ovulation
- 44 Luteal Phase Support in Assisted Reproduction
- 45 Thrombophilia and Implanation Failure
- 46 Intrauterine Insemination
- 47 The Prediction and Management of Poor Responders in ART
- 48 Oocyte Donation
- 49 In Vitro Maturation of Human Oocytes
- 50 Oocyte and Embryo Freezing
- 51 Cryopreservation of Male Gametes
- 52 The Management of Azoospermia
- 53 Spermatid Injection: Current Status
- 54 Optimizing Embryo Transfer
- 55 Single Embryo Transfer
- 56 Blastocyst Transfer
- 57 Clinical Significance of Embryo Multinucleation
- 58 Quality and Risk Management in the IVF Laboratory
- 59 The Nurse and REI
- 60 Understanding Factors That Influence the Assessment of Outcomes in Assisted Reproductive Technologies
- 61 The Revolution of Assisted Reproductive Technologies: How Traditional Chinese Medicine Impacted Reproductive Outcomes in the Treatment of Infertile Couples
- 62 Complications of Assisted Reproductive Technology
- 63 Ectopic and Heterotopic Pregnancies Following in Vitro Fertilization
- 64 The Impact of Oxidative Stress on Female Reproduction and ART: An Evidence-Based Review
- 65 PGD for Chromosomal Anomalies
- 66 Preimplantation Genetic Diagnosis for Single-Gene Disorders
- 67 Epigenetics and ART
- 68 Congenital Anomalies and Assisted Reproductive Technology
- PART IV ETHICAL DILEMMAS IN FERTILITY AND ASSISTED REPRODUCTION
- Index
- Plate section
- References
49 - In Vitro Maturation of Human Oocytes
from PART III - ASSISTED REPRODUCTION
Published online by Cambridge University Press: 04 August 2010
- Frontmatter
- Contents
- Contributors
- Foreword
- Preface
- Introduction
- PART I PHYSIOLOGY OF REPRODUCTION
- PART II INFERTILITY EVALUATION AND TREATMENT
- PART III ASSISTED REPRODUCTION
- 38 Medical Strategies to Improve ART Outcome: Current Evidence
- 39 Surgical Preparation of the Patient for In Vitro Fertilization
- 40 IVF in the Medically Complicated Patient
- 41 Polycystic Ovary Syndrome and IVF
- 42 Endometriosis and Assisted Reproductive Technology
- 43 Evidence-Based Medicine Comparing hMG/FSH and Agonist/Antagonist and rec/Urinary hCG/LH/GnRH to Trigger Ovulation
- 44 Luteal Phase Support in Assisted Reproduction
- 45 Thrombophilia and Implanation Failure
- 46 Intrauterine Insemination
- 47 The Prediction and Management of Poor Responders in ART
- 48 Oocyte Donation
- 49 In Vitro Maturation of Human Oocytes
- 50 Oocyte and Embryo Freezing
- 51 Cryopreservation of Male Gametes
- 52 The Management of Azoospermia
- 53 Spermatid Injection: Current Status
- 54 Optimizing Embryo Transfer
- 55 Single Embryo Transfer
- 56 Blastocyst Transfer
- 57 Clinical Significance of Embryo Multinucleation
- 58 Quality and Risk Management in the IVF Laboratory
- 59 The Nurse and REI
- 60 Understanding Factors That Influence the Assessment of Outcomes in Assisted Reproductive Technologies
- 61 The Revolution of Assisted Reproductive Technologies: How Traditional Chinese Medicine Impacted Reproductive Outcomes in the Treatment of Infertile Couples
- 62 Complications of Assisted Reproductive Technology
- 63 Ectopic and Heterotopic Pregnancies Following in Vitro Fertilization
- 64 The Impact of Oxidative Stress on Female Reproduction and ART: An Evidence-Based Review
- 65 PGD for Chromosomal Anomalies
- 66 Preimplantation Genetic Diagnosis for Single-Gene Disorders
- 67 Epigenetics and ART
- 68 Congenital Anomalies and Assisted Reproductive Technology
- PART IV ETHICAL DILEMMAS IN FERTILITY AND ASSISTED REPRODUCTION
- Index
- Plate section
- References
Summary
DEVELOPMENT OF IN VITRO MATURATION
The history of in vitro maturation (IVM) of oocytes goes back to as far as the 1930s (1) to Pincus, Enzman, and Saunders who studied the maturation of mammalian oocytes including human oocytes in vivo and in vitro (1, 2). Pincus and his colleagues observed that when oocytes were removed from the follicles and cultured in the laboratory without hormones, they spontaneously resumed meiosis and progressed to the mature stage, metaphase II (MII), as they do in vivo. In 1965, Edwards (3, 4) described the kinetics of in vitro oocyte maturation both in animals – mice, sheep, cows, pigs, and rhesus monkeys – and in humans. He introduced tissue culture medium 199 (TCM-199) for IVM and showed that meiosis is resumed in 80 percent of immature oocytes independent of cycle day and gonadotropin support. He subsequently concluded that “human oocytes can be fertilized after maturation in-vitro.”
In 1983, Veeck et al. reported two pregnancies resulting from in vitro matured oocytes (5). These morphologically immature oocytes were recovered from human menopausal gonadotropin and/or follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG) primed cycles in an in vitro fertilization (IVF) program.
Cha et al. published the first birth resulting from the fertilization of in vitro matured oocytes, which were harvested from an unstimulated ovary on cycle day 13 in an oocyte donation program (6). They also mentioned in the same report that immature oocytes were recovered from unstimulated ovaries both in proliferative and secretory phases.
Keywords
- Type
- Chapter
- Information
- Infertility and Assisted Reproduction , pp. 448 - 455Publisher: Cambridge University PressPrint publication year: 2008